Low-dose aspirin primary prevention study published
The Aspirin for Asymptomatic Atherosclerosis (AAA) study, which was initially presented at a conference last year, has now been published in full.
AAA examined whether primary prevention using low-dose aspirin was beneficial in people identified as being at increased cardiovascular risk by having a low reduced ankle-brachial index (ABI). The ABI is the ratio of systolic BP at the ankle to that in the arm and is considered to be an indicator of sub-clinical atherosclerosis.
NHS Choices reported on the original conference presentation and has produced an updated report. This discusses the study's main result, that there was no significant benefit from low-dose aspirin in this group.
JAMA 2010; 303: 841-8 (link to abstract); JAMA 2010; 303: 880-2 (Editorial, link to extract)